HER2-positive breast cancer chemotherapy can be safely omitted in about 30% of patients, five-year PHERGain trial data ...

New laboratory research shows that the protein SOCS3 suppresses glioblastoma cell growth and triggers mitochondrial ...

A prospective study of 48 patients links dual-tracer FDG and FAPI-04 PET/CT measurements to aggressive pathological features ...

Extensive-stage small-cell lung cancer (ES-SCLC) represents a particularly deadly subset of lung cancer for which outcomes ...

PHERGain five-year results show 92.4% iDFS in selected HER2-positive breast cancer patients avoiding chemotherapy, with ...

Convincing data for unmet need in third-line or later, but second-line data muddy the resu ...

Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies ...

Company AnnouncementCOPENHAGEN, Denmark; October 28, 2026Phase 3 LiGeR-HN1 trial of Petosemtamab in combination with pembrolizumabversus ...

(Biokin) reported positive results from a prespecified interim analysis in the randomized, multicenter Phase 3 PANKU-Lung01 ...

Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, ...

Explore modern inflammatory breast cancer diagnosis, trimodality treatment, subtype-specific therapies, and emerging clinical ...

Nice to meet you! I'm Ryo, a dad being tossed around daily by my 1-year-and-8-month-old tomboy daughter (the absolute boss of ...